Rodney P Rocconi MD

Gynecologic Oncology

Professor of Gynecologic Oncology, University of Alabama at Birmingham Associate Director, Infirmary Cancer Care Director of Research, Infirmary Cancer Care Specializing in preventing, diagnosing, and treating gynecological cancers

Join to View Full Profile

1660 Springhill AvenueMobile, AL 36640
Phone+1 251-410-1010
Fax+1 251-665-8010

Summary

Dr. Rodney P. Rocconi is a Gynecologic Oncologist, specializing in preventing, diagnosing and treating gynecological cancers. He completed a Fellowship at the University of Alabama at Birmingham in Birmingham, AL. He is an Associate Director for Clinical Research

Rodney P. Rocconi, M.D., F.A.C.O.G. | USA Health

Rodney P. Rocconi, M.D., joined Mitchell Cancer Institute (MCI) as a physician-scientist in the Gynecologic Oncology Service in 2007. He was the first MCI Abrah

Education & Training

University of Alabama Medical CenterResidency, Obstetrics and Gynecology, 2000 - 2004
University of Alabama School of MedicineClass of 2000
University of Alabama Medical CenterFellowship, Gynecologic Oncology

Certifications & Licensure

AL State Medical License 2001 - 2025
MS State Medical License 2023 - 2025
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Fellow (FACOG) American Congress of Obstetricians and Gynecologists

Clinical Trials

Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Start of enrollment: 2009 Apr 01
Completed
Phase 3
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Start of enrollment: 2009 Mar 23
Active, not recruiting
Phase 3
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Start of enrollment: 2009 Jun 29
Active, not recruiting
Phase 3
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Start of enrollment: 2009 Aug 17
Active, not recruiting
Phase 3
Racial and Genetic Biomarkers of Response in Tissue Samples From Patients With Endometrial Cancer
COMPLETED
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Start of enrollment: 2012 Jan 09
Completed
Phase 3
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Start of enrollment: 2011 Dec 12
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

ASO Visual Abstract: Conversion from Minimally Invasive Surgical Approaches to Open Surgery Among Endometrial Cancer Patients in the SGO Clinical Outcomes Registry.
Abdelrahman Yousif, Julie Ngo, Deena Abdel-Gadir, Rodney P Rocconi, Patrick Timmins
Annals of Surgical Oncology. 2025-03-24
Conversion from Minimally Invasive Surgical Approaches to Open Surgery Among Patients with Endometrial Cancer in the SGO Clinical Outcomes Registry.
Abdelrahman Yousif, Julie Ngo, Deena Abdel-Gadir, Rodney P Rocconi, Patrick Timmins
Annals of Surgical Oncology. 2025-02-21
Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial.
Iris L Romero, Ernst Lengyel, Andrea E Wahner Hendrickson, Gustavo C Rodriguez, Charles A Leath 3rd
Gynecologic Oncology. 2025-02-08

Press Mentions

As UMMC Continues Decade-Long Quest for Cancer Designation, Former Leaders Say the Medical Center Previously Lacked Commitment to Cancer CareFebruary 27th, 2025
Mississippi Couple Commits $25 Million Gift to Benefit UMMC Cancer Care, ResearchJanuary 21st, 2025
Gradalis to Host Key Opinion Leader Webinar on Unmet Medical Needs in Ovarian Cancer and the Company’s Immuno-Oncology Treatment, Vigil®September 28th, 2022
Join now to see all